|
市場調査レポート
異常脂質血症治療薬動向：スタチンの特許期限満了による拡大の持続可能性
The Dyslipidemia Market: Can Growth Be Sustained as Statin Patents Expire?
|
当商品の販売は、2011年12月21日を持ちまして終了しました。
Abstract
In This Issue.
Dyslipidemia is a key independent risk factor for cardiovascular disease
(CVD); CVD is the largest therapeutic segment of the world pharmaceutical
market, and treatment of dyslipidemia represents a major sector of the CVD
market. This report provides an overview of the condition, its role in CVD,
and its prevalence. We discuss dyslipidemia treatments, with a focus on the
statins as the dominant treatment choice worldwide. We review key patent
expiries, including the imminent U.S. expiries of pravastatin (Bristol-Myers
Squibb's Pravachol) and simvastatin (Merck & Co.'s Zocor) and the expected
2011 patent expiry of the best-selling statin, atorvastatin (Pfizer's
Lipitor). In addition, we discuss emerging agents in this market, highlighting
the effect generic agents may have on their adoption, or the effect these new
agents may have on generics erosion of the market. Finally, we present our
expectations for the market throughout our 2004-2014 forecast period.
Table of Contents
Statins and the Cardiovascular Market
Overview of Dyslipidemia
- Lipoproteins in the Blood
- Dyslipidemia and Cardiovascular Disease
- Prevalence of Dyslipidemia
Current Treatments
- Statins
- Fibrates
- Cholesterol Modulators
- Bile Acid Sequestrants
- Nicotinic Acid (Niacin)
- Cholesterol Absorption Inhibitors
- Combination Products
Current Market Status
- United States
- Europe
- Japan
Key Patent Expiries
Agents in Development
- PPAR Agonists
- Cholesterol Modulators
- CETP Inhibitors
- ACAT Inhibitors
- Nicotinic Acid Antagonists
- Squalene Synthetase Inhibitors
- Combination Products
- Lp-PLA2 Inhibitor
- Statins
Market Outlook
- United States
- Europe
- Japan
|
